Skip to content

Study · Case report or series · n = 1 · 2025

6 results

Bariatric surgery and semaglutide in a youth with juvenile Huntington disease and severe obesity: a case report.

Vidmar AP, Martin MJ, Abel S, Kim AG, Muñoz CE, Weitzner M, Derrington SF, Samakar K

Journal of medical case reports21 Oct 2025

PMID41121434 (opens in a new tab)PMCIDPMC12538795 (opens in a new tab)DOI10.1186/s13256-025-05615-2 (opens in a new tab)PepBankPUB-41121434
Read at sourcePubMedAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study6

2 results from studies that gave the peptide. 2 results from people.

  1. 01HumanCase report or seriesEfficacy outcome

    In a 17-year-old with juvenile Huntington disease and severe obesity, body mass index fell by 7% (to 40 kg/m2) after 3 months of semaglutide.

    In plain wordsA teenager with Huntington disease and severe obesity had a 7% lower BMI after 3 months on semaglutide.

    Peptide
    Semaglutide
    Outcome
    DecreaseBMI after 3 months of semaglutide
    Study

    n = 1

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    0.25 mg weekly, titrated up to 1 mg · 3 monthsAs given in this study (human).

    Measurements

    BMI reduction
    7%
    3 months semaglutide
    BMI
    40 kg/m2
    after 3 months

    Source sentences

    Summary
    After 3 months, his body mass index reduced by 7% (40 kg/m2).
    2 context sentences
    Summary · context
    Semaglutide was initiated at 0.25 mg weekly, titrating up to 1 mg.
    Summary · context
    A 17-year-old Hispanic male with juvenile Huntington disease and a body mass index of 44 kg/m2 (190% of the 95th percentile) presented for obesity management.
  2. 02HumanCase report or seriesEfficacy outcome

    In the same 17-year-old, obesity-related complications, including elevated liver enzymes and obstructive sleep apnea, continued despite semaglutide.

    In plain wordsThe teenager still had raised liver enzymes and sleep apnea despite semaglutide treatment.

    Peptide
    Semaglutide
    Outcome
    No significant changeObesity-related complications after semaglutide
    Study

    n = 1

    Outcome group
    Liver fat and liver function · Metabolic and weight
    Studied dose
    0.25 mg weekly, titrated up to 1 mg · 3 monthsAs given in this study (human).

    Source sentences

    Summary
    Despite this, he continued to experience obesity-related complications, including elevated liver enzymes and obstructive sleep apnea
    1 context sentence
    Summary · context
    A 17-year-old Hispanic male with juvenile Huntington disease and a body mass index of 44 kg/m2 (190% of the 95th percentile) presented for obesity management.

Studies that did not test the peptide alone4

In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Semaglutide.

  1. 03HumanNot a test of Semaglutide aloneCase report or seriesEfficacy outcome

    In a youth with juvenile Huntington disease, BMI decreased to 33 kg/m2 six months after laparoscopic sleeve gastrectomy that followed semaglutide treatment.

    In plain wordsThe teenager's BMI fell to 33 six months after weight-loss surgery that followed semaglutide; the effect cannot be split between the two.

    Peptide
    Semaglutide
    Outcome
    DecreaseBMI after semaglutide and sleeve gastrectomy
    Study

    n = 1

    Outcome group
    Body weight · Metabolic and weight

    Measurements

    BMI
    33 kg/m2
    6 months after surgery

    Source sentences

    Summary
    Six-months postoperatively, his body mass index decreased to 33 kg/m2, liver enzyme levels improved, and his sleep apnea resolved.
    1 context sentence
    Summary · context
    A 17-year-old Hispanic male with juvenile Huntington disease and a body mass index of 44 kg/m2 (190% of the 95th percentile) presented for obesity management.

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

  2. 04HumanNot a test of Semaglutide aloneCase report or seriesEfficacy outcome

    In a youth with juvenile Huntington disease, liver enzyme levels improved six months after sleeve gastrectomy that followed semaglutide treatment.

    In plain wordsThe teenager's liver enzymes improved after weight-loss surgery that followed semaglutide; the effect cannot be split between the two.

    Peptide
    Semaglutide
    Outcome
    DecreaseLiver enzymes after semaglutide and sleeve gastrectomy
    Study

    n = 1

    Outcome group
    Liver fat and liver function · Liver

    Source sentences

    Summary
    Six-months postoperatively, his body mass index decreased to 33 kg/m2, liver enzyme levels improved, and his sleep apnea resolved.
    1 context sentence
    Summary · context
    A 17-year-old Hispanic male with juvenile Huntington disease and a body mass index of 44 kg/m2 (190% of the 95th percentile) presented for obesity management.

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

  3. 05HumanNot a test of Semaglutide aloneCase report or seriesEfficacy outcome

    In a youth with juvenile Huntington disease, sleep apnea resolved six months after sleeve gastrectomy that followed semaglutide treatment.

    In plain wordsThe teenager's sleep apnea went away after weight-loss surgery that followed semaglutide; the effect cannot be split between the two.

    Peptide
    Semaglutide
    Outcome
    DecreaseSleep apnea after semaglutide and sleeve gastrectomy
    Study

    n = 1

    Outcome group
    Sleep · Sleep

    Source sentences

    Summary
    Six-months postoperatively, his body mass index decreased to 33 kg/m2, liver enzyme levels improved, and his sleep apnea resolved.
    1 context sentence
    Summary · context
    A 17-year-old Hispanic male with juvenile Huntington disease and a body mass index of 44 kg/m2 (190% of the 95th percentile) presented for obesity management.

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

  4. 06HumanNot a test of Semaglutide aloneCase report or seriesEfficacy outcome

    In a youth with juvenile Huntington disease, physical activity and quality of life improved after semaglutide followed by sleeve gastrectomy.

    In plain wordsThe teenager reported more physical activity and a better quality of life after semaglutide and weight-loss surgery together.

    Peptide
    Semaglutide
    Outcome
    IncreasePhysical activity and quality of life after semaglutide and surgery
    Study

    n = 1

    Outcome group
    Exercise and physical function · Whole body

    Source sentences

    Summary
    Additionally, he reported improved physical activity and enhanced quality of life.
    1 context sentence
    Summary · context
    A 17-year-old Hispanic male with juvenile Huntington disease and a body mass index of 44 kg/m2 (190% of the 95th percentile) presented for obesity management.

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 00:04 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.